34 results
Keyword Everolimus Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Afinitor (updated)
everolimus, Carcinoma, Renal Cell, Breast Neoplasms, Pancreatic Neoplasms
Date of authorisation: 02/08/2009, Revision: 23, Authorisedreport Afinitor everolimus Procedure No.: EMEA/H/C/001038/II/0020 … Presentations: Afinitor everolimus See Annex A The following … cells11,12,13. Coadministration of everolimus and AI in breast cancer cells … -
List item
Human medicine European public assessment report (EPAR): Votubia
everolimus, Tuberous Sclerosis
Date of authorisation: 02/09/2011,
, Revision: 24, Authorised
EMEA/H/C/002311 Votubia (everolimus) An overview of Votubia … contains the active substance everolimus. Tuberous sclerosis is … Votubia (Votubia (everolimus) EMA/229443/2018 Page … -
List item
Human medicine European public assessment report (EPAR): Kisplyx
lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016,
, Revision: 7, Authorised
another cancer medicine called everolimus. Kisplyx contains the active … combination with 5 mg of everolimus once a day. The dose of Kisplyx … and the medicine containing everolimus. Kisplyx EMA/577485/2016 … -
List item
Human medicine European public assessment report (EPAR): Cabometyx
cabozantinib s-malate, Carcinoma, Renal Cell
Date of authorisation: 09/09/2016,, Revision: 4, Authorised
survival (PFS) compared with everolimus: PFS was 7.4 months with Cabometyx … Cabometyx versus 3.8 months with everolimus [HR=0.58 (0.45, 0.74), p … with the cancer medicine everolimus. Patients treated with Cabometyx … -
List item
Human medicine European public assessment report (EPAR): Opdivo (updated)
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015,, Revision: 24, Authorised
Opdivo was compared with everolimus (another cancer medicine … months for patients given everolimus. One main study involving … -
List item
Human medicine European public assessment report (EPAR): Lutathera (updated)
lutetium (177Lu) oxodotreotide, Neuroendocrine Tumors
Date of authorisation: 26/09/2017,, , Revision: 2, Authorised
-
List item
Human medicine European public assessment report (EPAR): Ibrance (updated)
palbociclib, Breast Neoplasms
Date of authorisation: 09/11/2016,, Revision: 7, Authorised
-
List item
Human medicine European public assessment report (EPAR): Scenesse (updated)
afamelanotide, Protoporphyria, Erythropoietic
Date of authorisation: 22/12/2014,, , 
, Revision: 3, Authorised
-
List item
Human medicine European public assessment report (EPAR): Fotivda
tivozanib, Carcinoma, Renal Cell
Date of authorisation: 24/08/2017,, Revision: 2, Authorised
-
List item
Human medicine European public assessment report (EPAR): Inlyta
axitinib, Carcinoma, Renal Cell
Date of authorisation: 03/09/2012, Revision: 9, Authorised -
List item
Human medicine European public assessment report (EPAR): Xermelo
telotristat etiprate, Carcinoid Tumor, Neuroendocrine Tumors
Date of authorisation: 17/09/2017,, , Revision: 3, Authorised
-
List item
Human medicine European public assessment report (EPAR): SomaKit TOC
edotreotide, Neuroendocrine Tumors, Radionuclide Imaging
Date of authorisation: 08/12/2016,, , Revision: 3, Authorised
-
List item
Human medicine European public assessment report (EPAR): Ketoconazole HRA
Ketoconazole, Cushing Syndrome
Date of authorisation: 18/11/2014,, , Revision: 8, Authorised
-
List item
Human medicine European public assessment report (EPAR): Kisqali
ribociclib succinate, Breast Neoplasms
Date of authorisation: 22/08/2017,, Revision: 1, Authorised
-
List item
Human medicine European public assessment report (EPAR): Exviera
dasabuvir sodium, Hepatitis C, Chronic
Date of authorisation: 14/01/2015,, Revision: 15, Authorised
-
List item
Human medicine European public assessment report (EPAR): Opsumit
Macitentan, Hypertension, Pulmonary
Date of authorisation: 20/12/2013,, Revision: 13, Authorised
-
List item
Human medicine European public assessment report (EPAR): Rapamune
Sirolimus, Graft Rejection, Kidney Transplantation
Date of authorisation: 13/03/2001, Revision: 38, Authorised -
List item
Human medicine European public assessment report (EPAR): Darunavir Krka d.d.
darunavir, HIV Infections
Date of authorisation: 18/01/2018,
, Revision: 2, Authorised
-
List item
Human medicine European public assessment report (EPAR): Faslodex
fulvestrant, Breast Neoplasms
Date of authorisation: 09/03/2004, Revision: 19, Authorised -
List item
Human medicine European public assessment report (EPAR): Tagrisso
osimertinib mesylate, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 01/02/2016,, Revision: 8, Authorised
-
List item
Human medicine European public assessment report (EPAR): Stivarga
regorafenib, Colorectal Neoplasms
Date of authorisation: 26/08/2013, Revision: 14, Authorised -
List item
Human medicine European public assessment report (EPAR): Alecensa
alectinib hydrochloride, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 16/02/2017,, Revision: 7, Authorised
-
List item
Human medicine European public assessment report (EPAR): Lojuxta
Lomitapide, Hypercholesterolemia
Date of authorisation: 31/07/2013,, , Revision: 10, Authorised
-
List item
Human medicine European public assessment report (EPAR): Imbruvica
Ibrutinib, Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
Date of authorisation: 21/10/2014,, , Revision: 12, Authorised
-
List item
Human medicine European public assessment report (EPAR): Zelboraf
vemurafenib, Melanoma
Date of authorisation: 17/02/2012, Revision: 18, Authorised